RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Tolerance to psilocybin appears after a single dose and dissipates dissipates after a few days. A cross-tolerance can develop between psilocybin and other classical psychedelics such as LSD, mescaline and DOM. Repeated use of psilocybin does not lead to physical dependence or drug withdrawal. Despite the rapid onset of tolerance, rates of self-administration in Rhesus macaques are low, which usually indicates a low abuse potential. A 2008 study concluded that, based on U.S. data from 2000 to 2002, adolescent-onset usage of hallucinogenic drugsdid not increase the risk of drug dependence in adulthood; this was in contrast to adolescent usage of cannabis, cocaine, inhalants, anxiolytic medicines, and stimulants, all of which were associated with "an excess risk of developing clinical features associated with drug dependence". Multiple studies in 2010 ranked the relative harm of psilocybin mushrooms below all other drugs in a selection of 19 recreational drugs, including alcohol, cannabis, cocaine, ecstasy, heroin, and tobacco.
Autotrophs that produced organic compounds from CO2, either photosynthetically or by inorganic chemical reactions; Heterotrophs that obtained organics from leakage of other organisms Saprotrophs that absorbed nutrients from decaying organisms Phagotrophs that were sufficiently complex to envelop and digest particulate nutrients, including other organisms. The eukaryotic cell seems to have evolved from a symbiotic community of prokaryotic cells. DNA-bearing organelles like mitochondria and chloroplasts are remnants of ancient symbiotic oxygen-breathing bacteria and cyanobacteria, respectively, where at least part of the rest of the cell may have been derived from an ancestral archaean prokaryote cell. The archean prokaryote cell concept is often termed as the endosymbiotic theory. There is still debate about whether organelles like the hydrogenosome predated the origin of mitochondria, or vice versa: see the hydrogen hypothesis for the origin of eukaryotic cells. How the current lineages of microbes evolved from this postulated community is currently unsolved, but subject of extensive research by biologists, stimulated by new discoveries in genome science.
Richard Laurence Millington Synge (28 October 1914 – 18 August 1994) was an English biochemist, and shared the 1952 Nobel Prize in Chemistry for the invention of partition chromatography with Archer Martin.
== Interactions == EMP has been reported to increase the efficacy and toxicity of tricyclic antidepressants like amitriptyline and imipramine. When products containing calcium, aluminium, and/or magnesium, such as dairy products like milk, various foods dietary supplements, and antacids, are consumed concomitantly with EMP, an insoluble chelate complex/phosphate salt between EMP and these metals can be formed, and this can markedly impair the absorption and hence oral bioavailability of EMP. There may be an increased risk of angioedema in those concurrently taking ACE inhibitors.
== Applications == Immunoliposome applications use its ability to act as a drug delivery system and release specific drug components to target cells. This mechanism can be specifically highlighted in cancer cell targeting and through nutrient delivery systems.
Sources: en.wikipedia.org
Analytical application of the radiotracer method is a forerunner of isotope dilution. This method was developed in the early 20th century by George de Hevesy for which he was awarded the Nobel Prize in Chemistry for 1943. An early application of isotope dilution in the form of radiotracer method was determination of the solubility of lead sulphide and lead chromate in 1913 by George de Hevesy and Friedrich Adolf Paneth. In the 1930s, US biochemist David Rittenberg pioneered the use of isotope dilution in biochemistry enabling detailed studies of cell metabolism.
=== Names === Levodopa is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, DCITTooltip Denominazione Comune Italiana, and JANTooltip Japanese Accepted Name.
=== Hormonal evaluation === Similar to humans, a diagnosis of hypersomatotropism in cats and dogs requires demonstration of growth hormone excess or heightened IGF-1 concentrations. Growth hormone levels can be measured with a radioimmunoassay. However the cost may impact availability of this. All cats with hypersomatotropism that have been tested in studies displayed increased growth hormone levels. Some cats had significantly increased levels; in other cats, the increase was only slightly above normal levels. Cats in those studies were likely in the later stages of the disease. A single instance of elevated growth hormone levels is not indicative of hypersomatotropism, it can be the result of a secretory pulse and mildly increased growth hormone levels have been observed in diabetic cats without hypersomatotropism. The recommended practice is for several tests with 10 minute intervals. IGF-1 levels can be detected with a blood test. The vast majority of cats with hypersomatotropism have increased IGF-1 levels, most dogs with hypersomatotropism have increased IGF-1 levels. Normal levels of IGF-1 have been seen in a few cats, potentially due to these cats being at the early stages of the disease. Other causes need to be investigated in cats with normal IGF-1 levels and suspected hypersomatotropism. IGF-1 levels may be lower due to lymphoma or other diseases. IGF-1 levels can be normal in cats with hypersomatotropism when the measurement is taken prior to insulin therapy.
Taco Bell began experimenting with fast-casual and urban concepts when it created U.S. Taco Co. and Urban Taproom in 2014 reflecting a market shift due to the popularity of Chipotle Mexican Grill. The menu consisted of tacos with American fillings, and did not sell the food sold in Taco Bell restaurants, such as burritos. It was launched in Huntington Beach, California, in August 2014. U.S. Taco Co. closed on September 15, 2015, so the company could focus on its new similar Taco Bell Cantina concept, which featured special menu items and served alcohol. It opened its first location a few days later in Chicago's Wicker Park neighborhood, followed by a location in San Francisco about a month later, located less than a block away from AT&T Park. In 2016, Taco Bell launched the Taco Bell Cantina flagship store located on the Las Vegas Strip. The 24-hour restaurant serves alcohol, unique menu items, and features a DJ. It was announced in August 2017 that the store would begin hosting weddings. Taco Bell Cantina currently has locations in San Francisco, Berkeley, Chicago (2 locations), Las Vegas, Austin, Fayetteville, Cincinnati, Cleveland, Atlanta, Newport Beach, San Diego, San Jose, Sacramento, Nashville, with them once having plans to open soon in Somerville, Massachusetts, but as of 2025, there are instead Taco Bell Cantinas in Brookline and Allston, Massachusetts. In March 2020, Taco Bell announced that it would be converting 3 of its suburban stores into Cantinas that year as part of a test run.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.